Bavarian Nordic A/S (VIE:BAVA)

Market Cap	2.05B -0.5%
Revenue (ttm)	922.11M +13.5%
Net Income	327.37M +118.6%
EPS	4.13 +116.3%
Shares Out	n/a
PE Ratio	6.25
Forward PE	19.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	25.90
Previous Close	26.47
Day's Range	25.90 - 26.50
52-Week Range	17.92 - 32.52
Beta	n/a
RSI	51.69
Earnings Date	Mar 12, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,738
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: BAVA

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK